The inefficiency of recombinant tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-based clinical regimens has been dominantly attributed to the short half-life of TRAIL. Affinity-controlled release using endogenous long-acting proteins, such as IgG and albumin, as carriers is extremely attractive for improving the pharmacokinetics of TRAIL. Up to now, it is unclear whether IgG-binding is efficient for affinity-controlled release of TRAIL.

中文翻译：

---

内源性基于TRAIL的IgG亲和力控制释放发挥卓越的抗肿瘤作用

重组肿瘤坏死因子相关的凋亡诱导配体（TRAIL）为基础的临床方案的无效性主要归因于TRAIL的半衰期短。使用内源性长效蛋白（例如IgG和白蛋白）作为载体进行亲和力控制释放对于改善TRAIL的药代动力学极为有吸引力。到目前为止，尚不清楚IgG结合对于TRAIL的亲和力控制释放是否有效。